NCT04387760
Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial
  1. Study Type
  2. Interventional
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Parallel/Crossover
  1. Intervention Assignment
  2. Randomised
  1. Population (7)
  2. Male and Female
  3. COVID-19
  4. Adult
  5. Aged (65+)
  1. Intervention (1)
  2. Favipiravir
  1. Comparison (1)
  2. Hydroxychloroquine
  1. Outcome (6)
  2. Viral load
  3. Adverse Event
  4. Death
  5. Respiratory support
  6. Admission to Intensive Care Unit
  7. Serum lactate measurement
References (1)
References (1)
NCT04362332
An Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19
  1. Study Type
  2. Interventional
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Parallel/Crossover
  1. Intervention Assignment
  2. Randomised
  1. Population (9)
  2. Male and Female
  3. Hospitalization
  4. COVID-19
  5. NEWS2 Score
  6. Adult
  7. Aged (65+)
  1. Intervention (4)
  2. Chloroquine
  3. Supportive care
  4. Hydroxychloroquine
  1. Comparison (1)
  2. Support
  1. Outcome (5)
  2. Adverse Event
  3. Treatment discontinued
  4. Death
  5. NEWS2 Score
  6. Admission to Intensive Care Unit
References (1)
NCT04355026
Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia
  1. Study Type
  2. Interventional
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Parallel/Crossover
  1. Intervention Assignment
  2. Randomised
  1. Population (8)
  2. Male and Female
  3. Hospitalization
  4. COVID-19
  5. Adult
  6. Aged (65+)
  1. Intervention (2)
  2. Hydroxychloroquine
  3. Bromhexine
  1. Comparison (1)
  2. Hydroxychloroquine
  1. Outcome (6)
  2. Nosocomial Pneumonia
  3. Oxygen Supplementation
  4. Length of ICU Stay
  5. Mechanical ventilation
  6. Duration Of Hospital Stay
  7. Duration of Symptom
References (1)
Ip 2021
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study
  1. Study Type
  2. Observational
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Case series/Case control/Cohort
  1. Intervention Assignment
  2. Not Applicable
References (1)
Andy 2021
Smartphone electrocardiogram for QT interval monitoring in Coronavirus Disease 2019 (COVID-19) patients treated with Hydroxychloroquine
  1. Study Type
  2. Observational
  1. Study Aim
  2. Diagnostic/Prognostic
  3. Treatment and Management
  1. Study Design
  2. Case series/Case control/Cohort
  1. Intervention Assignment
  2. Not Applicable
References (1)
References (1)
NCT04423991
Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning: the IDENTIFY Trial
  1. Study Type
  2. Observational
  1. Study Aim
  2. Diagnostic/Prognostic
  1. Study Design
  2. Parallel/Crossover
  1. Intervention Assignment
  2. Not Applicable
References (2)
Meriglier 2020
Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection
  1. Study Type
  2. Observational
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Case series/Case control/Cohort
  1. Intervention Assignment
  2. Not Applicable
References (1)
Eveleens 2021
Effect of hydroxychloroquine on the cardiac ventricular repolarization - a randomized clinical trial
  1. Study Type
  2. Interventional
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Parallel/Crossover
  1. Intervention Assignment
  2. Randomised
References (1)
NCT04371406
Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients: Randomized Controlled Trial: MG-COVID
  1. Study Type
  2. Interventional
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Parallel/Crossover
  1. Intervention Assignment
  2. Randomised
  1. Population (7)
  2. Male and Female
  3. COVID-19
  4. Adult
  5. Aged (65+)
  1. Intervention (4)
  2. Azithromycin
  3. Hydroxychloroquine
  4. General Practitioner
  1. Comparison (1)
  2. Placebo
  1. Outcome (14)
  2. Serious Adverse Event
  3. Death
  4. Withdrawn From Research Study
  5. Time to clinical recovery
  6. Adverse Event
  7. Viral load
  8. Clinical status
  9. Hospitalization
  10. Oxygen Saturation
  11. Mechanical ventilation
  12. Oxygen Therapy
  13. Admission to Intensive Care Unit
  14. Antibiotic Therapy
References (1)
Mercuro 2020
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)
  1. Study Type
  2. Observational
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Case series/Case control/Cohort
  1. Intervention Assignment
  2. Not Applicable
References (1)
Su 2020aa
Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China
  1. Study Type
  2. Observational
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Case series/Case control/Cohort
  1. Intervention Assignment
  2. Not Applicable
References (1)
IRCT20200428047228N2
Hydroxychloroquine in comparison with hydroxychloroquine + azithromycin in patients with covid-19
  1. Study Type
  2. Interventional
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Parallel/Crossover
  1. Intervention Assignment
  2. Randomised
  1. Population (9)
  2. Male and Female
  3. Hospitalization
  4. COVID-19
  5. Adult
  6. Aged (65+)
  7. Child
  1. Intervention (2)
  2. Azithromycin
  3. Hydroxychloroquine
  1. Comparison (2)
  2. Hydroxychloroquine
  3. Placebo
  1. Outcome (10)
  2. Blood Count
  3. Death In Hospital
  4. Fever
  5. Length of ICU Stay
  6. C-reactive Protein
  7. Oxygen Saturation
  8. Dyspnea
  9. Computerised Tomography
  10. Adverse Drug Reaction
  11. Duration Of Hospital Stay
References (1)
0 Selected
ExportClear